

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). A method for ameliorating tissue damage related to vascular leakage or edema comprising contacting said tissue with a vascular permeability modulating amount of a pharmaceutical composition comprising a ~~Sre-family~~ human c-Src tyrosine kinase inhibitor.

Claim 2 (currently amended). The method of claim 1 wherein said ~~Sre-family~~ human c-Src tyrosine kinase inhibitor is a chemical inhibitor.

Claim 3 (currently amended). The method of claim 2 wherein said chemical inhibitor is selected from the group consisting of pyrazolopyrimidine PP1, pyrazolopyrimidine PP2, PD173955, ~~AGL1872~~, PD162531, Radicol R2146 and Geldanamycin.

Claim 4 (previously presented). The method of claim 3 wherein said inhibitor is pyrazolopyrimidine PP1.

Claims 5-16 (cancelled).

Claim 17 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating vascular permeability increase in a tissue suffering from a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of vascular leakage or edema associated disease conditions, and wherein said pharmaceutical composition comprises a ~~Sre-family~~ human c-Src tyrosine kinase inhibitor and a pharmaceutically acceptable carrier therefor.

Claim 18 (currently amended). An article of manufacture of claim 17 wherein said ~~Sre-family~~ human c-Src tyrosine kinase inhibitor is a chemical inhibitor.

Claim 19 (currently amended). An article of manufacture of claim 18 wherein said ~~Sre-family~~ human c-Src tyrosine kinase inhibitor is selected from the group consisting of pyrazolopyrimidine PP1, pyrazolopyrimidine PP2, PD173955, ~~AGL1872~~, PD162531, Radicol R2146 and Geldanamycin.

Claim 20 (currently amended). An article of manufacture of claim 18 wherein said ~~Sre-family~~ human c-Src tyrosine kinase inhibitor is pyrazolopyrimidine PP1.

Application No. 09/538,248 - - - - - 3

Claims 21-31 (cancelled).

Claim 32 (new). An article of manufacture of claim 18 wherein said human c-Src tyrosine kinase inhibitor is pyrazolopyrimidine PP2.

Claim 33 (new). The method of claim 3 wherein said human c-Src tyrosine kinase inhibitor is pyrazolopyrimidine PP2.